drugset / Trial / NCT07656090
Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid Tumors
Phase 0
Enrolling by invitation
19 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSequentialOpen-labelTreatment
Summary
This is an open-label, dose escalation, phase I study to evaluate safety tolerability, MTD or MFD, pharmacokinetic profile, immunogenicity, and pharmacodynamic profile of IDOV-Immune in patients with advanced solid tumors.
Timeline
- Start
- 2025-12-18
- Primary completion
- 2027-10-31
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IDOV-Immune | Unknown | 1e+07 unknown | Intravenous |
| Subject | IDOV-Immune | Unknown | 1e+08 unknown | Intravenous |
| Subject | IDOV-Immune | Unknown | 1e+09 unknown | Intravenous |
| Subject | IDOV-Immune | Unknown | 1e+10 unknown | Intravenous |